Evidence map›Paper›PMID 34492068›Full record

ArticlePloS one2021

Random forest-integrated analysis in AD and LATE brain transcriptome-wide data to identify disease-specific gene expression.

Xinxing Wu, Chong Peng, Peter T Nelson, Qiang Cheng

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xinxing WuUniversity of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0001-9177-9352
Chong PengQingdao University, Qingdao, Shandong, China.ORCID 0000-0003-0003-5126
Peter T NelsonUniversity of Kentucky, Lexington, Kentucky, United States of America.
Qiang ChengUniversity of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0002-3596-2838

Funding

Small vessel disease biomarkers in a longitudinally-followed "stroke-belt" cohortUH3NS100606 · NINDS · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, WILCOCK, DONNA M · 2018 to 2020
$3.4M
Noninvasive Noncontact High-Density Optical Imaging of Neonatal Intraventricular HemorrhageR01HD101508 · NICHD · UNIVERSITY OF KENTUCKY · PI YU, GUOQIANG · 2020 to 2024
$2.7M
Continuous and Longitudinal Monitoring of Cerebral Blood Flow and Metabolism in Freely Moving RodentsR56NS117587 · NINDS · UNIVERSITY OF KENTUCKY · PI YU, GUOQIANG · 2020 to 2020
$613k
Gene Profile Analysis of Associations between Alzheimer’s Disease and Circadian Rhythmic Patterns of Human Brain Regions Using Machine LearningR21AG070909 · NIA · UNIVERSITY OF KENTUCKY · PI CHENG, QIANG · 2021 to 2021
$421k
NIA NIH HHS R21 AG070909NICHD NIH HHS R01 HD101508NINDS NIH HHS R56 NS117587NINDS NIH HHS UH3 NS100606
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a complex neurodegenerative disorder that affects thinking, memory, and behavior. Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently identified common neurodegenerative disease that mimics the clinical symptoms of AD. The development of drugs to prevent or treat these neurodegenerative diseases has been slow, partly because the genes associated with these diseases are incompletely understood. A notable hindrance from data analysis perspective is that, usually, the clinical samples for patients and controls are highly imbalanced, thus rendering it challenging to apply most existing machine learning algorithms to directly analyze such datasets. Meeting this data analysis challenge is critical, as more specific disease-associated gene identification may enable new insights into underlying disease-driving mechanisms and help find biomarkers and, in turn, improve prospects for effective treatment strategies. In order to detect disease-associated genes based on imbalanced transcriptome-wide data, we proposed an integrated multiple random forests (IMRF) algorithm. IMRF is effective in differentiating putative genes associated with subjects having LATE and/or AD from controls based on transcriptome-wide data, thereby enabling effective discrimination between these samples. Various forms of validations, such as cross-domain verification of our method over other datasets, improved and competitive classification performance by using identified genes, effectiveness of testing data with a classifier that is completely independent from decision trees and random forests, and relationships with prior AD and LATE studies on the genes linked to neurodegeneration, all testify to the effectiveness of IMRF in identifying genes with altered expression in LATE and/or AD. We conclude that IMRF, as an effective feature selection algorithm for imbalanced data, is promising to facilitate the development of new gene biomarkers as well as targets for effective strategies of disease prevention and treatment.

Indexed as

AgedAged, 80 and overAlgorithmsAlzheimer DiseaseBiomarkersBrainBrain DiseasesCognitive DysfunctionDiagnosis, DifferentialDNA-Binding ProteinsFemaleGene Expression RegulationHumansImage Interpretation, Computer-AssistedMachine LearningMagnetic Resonance ImagingBiomarkersDNA-Binding ProteinsTARDBP protein, human

Identifiers

PMID34492068
PMCPMC8423259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.